Citations

Clear

2117 citation(s) found for "Mayo, Steven".

Longitudinal Evaluation of Sexual Function in a Male Cohort: The Olmsted County Study of Urinary Symptoms and Health Status Among Men
Gades, Naomi M. , Jacobson, Debra J., McGree, Michaela E. , Sauver, Jennifer L. St. , Lieber, Michael M., Nehra, Ajay, Jacobsen, Steven J. , Girman, Cynthia J. , St Sauver, Jennifer L

Mayo Clinic

The Journal of Sexual Medicine | June 29, 2009 | Volume: 6 | Issue: 9 | Pages: 2455-2466

10.1111/j.1743-6109.2009.01374.x | PMID 19570040 Get It

ABSTRACT Introduction The presence of erectile or ejaculatory dysfunction may indicate physical problems; however, individual perceptions (e.g., sexual satisfaction) may reflect the degree of concern about these changes. Long-term data showing how changes in multiple sexual function domains track together may be useful in understanding the importance of physical declines vs. sexual satisfaction. Aim The aim of this study was to describe changes in sexual function among a population-based sample of aging men. Methods A population-based cohort study using data from the Olmsted County Study of Urinary Symptoms and Health Status among Men. Sexual function was assessed biennially from 1996 to 2004 using a previously validated questionnaire in a random sample of 2,213 men. Main Outcome Measures Changes in erectile function, libido, ejaculatory function, sexual problems, and sexual satisfaction. Results Overall, we observed declines in all of the sexual function domains, ranging from an annual decrease of 0.03 point per year for sexual satisfaction to an annual decrease of 0.23 point per year in erectile function. Moderate correlations were observed among all longitudinal changes in sexual function (range in age-adjusted rs = 0.14–0.43); however, significantly smaller correlations between changes in the functional domains and changes in sexual satisfaction and problem assessment were observed among older men (range in age-adjusted rs = 0.03–0.29). Conclusion Overall, these results demonstrate that longitudinal changes in five sexual function domains change together over time in our community-based cohort. Erectile function, ejaculatory function, and sexual drive decrease over time with greater rates of decline for older men. However, older men may be less likely to perceive these declines as a problem and be dissatisfied. These data may prove helpful to patients and clinicians in understanding and discussing changes in multiple aspects of sexual function.
P4‐128: Association of a missense cathepsin D (CTSD) SNP with risk of Alzheimer's disease
Younkin, Linda H., Reinstatler, Lael , Peterson, Ronald C. , Graff‐Radford, Neill R. , Younkin, Steven G. , Ertekin‐Taner, Nilüfer , Burgess, Jeremy D. , Leissring, Malcolm A. , Ma, Li , Crook, Julia E. , Pankratz, V. Shane , Dickson, Dennis W.

Mayo Clinic

Alzheimer's & Dementia | June 25, 2009 | Volume: 5 | Issue: 4S_Part_15 | Pages: No page available

10.1016/j.jalz.2009.04.796 Get It

O4‐01‐06: Genetic variation in PCDH11X is associated with susceptibility to late‐onset Alzheimer's disease
Carrasquillo, Minerva M. , Zou, Fanggeng, Pankratz, V. Shane , Wilcox, Samantha L., Walker, Louise P., Younkin, Samuel , Younkin, Curtis, Younkin, Linda H., Bisceglio, Gina, Ertekin‐Taner, Nilüfer , Petersen, Ronald C. , Graff‐Radford, Neill R., Younkin, Steven G. , Carrasquillo, Minerva M. , Ma, Li , Crook, Julia E. , Dickson, Dennis W.

Mayo Clinic

Alzheimer's & Dementia | June 25, 2009 | Volume: 5 | Issue: 4S_Part_5 | Pages: No page available

10.1016/j.jalz.2009.05.518 Get It

O4‐01‐03: Genome‐Wide Association Study (GWAS) of plasma Aß levels in the dalmatian islands of Vis and korcula
Allen, Mariet , Younkin, Linda H., Campbell, Susan, Morgan, Joanne , Hastie, Nicholas D. , Campbell, Harry, Younkin, Steven G., Wright, Alan F., Ansari, Morad , Hayward, Caroline , Vitart, Véronique , Huffman, Jennifer E. , Polašek, Ozren , Rudan, Igor

Mayo Clinic

Alzheimer's & Dementia | June 25, 2009 | Volume: 5 | Issue: 4S_Part_5 | Pages: No page available

10.1016/j.jalz.2009.05.515 Get It

P3‐122: High plasma Aβ40 levels are associated with incident Cognitive Impairment not Demented (CIND) and dementia cases in persons of Mexican ancestry (SALSA study)
Graff‐Radford, Neill R., Lucas, John A. , Younkin, Linda H., Moore, Kari, Younkin, Steven G. , Haan, Mary N. , Graff‐Radford, Neill R., Crook, Julia E.

Mayo Clinic

Alzheimer's & Dementia | June 25, 2009 | Volume: 5 | Issue: 4S_Part_12 | Pages: No page available

10.1016/j.jalz.2009.04.1097 Get It

Malignant B Cells Skew the Balance of Regulatory T Cells and TH17 Cells in B-Cell Non-Hodgkin's Lymphoma
Yang, Zhi‐Zhang, Novak, Anne J. , Ziesmer, Steven C., Ansell, Stephen M. , Witzig, Thomas E.

Mayo Clinic

Cancer Research | June 10, 2009 | Volume: 69 | Issue: 13 | Pages: 5522-5530

10.1158/0008-5472.can-09-0266 | PMID 19509224 Get It

Abstract Using biopsy specimens from patients with B-cell non-Hodgkin's lymphoma, we observed a significantly low frequency of TH17 cells, including several samples with no detectable amount of interleukin (IL)-17–producing cells present in the tumor microenvironment. We found that, in the absence of lymphoma B cells, treatment with IL-1β/IL-6 or lipopolysaccharide (LPS) enhanced IL-17 expression in CD4+ T cells and this enhancement was attenuated when CD4+ T cells were cocultured with lymphoma B cells. Blockade of CD27-CD70 or CD28-CD80/86 interactions by anti-CD70 or anti-CD80/86 antibodies restored LPS-mediated induction of IL-17 expression in CD4+ T cells cocultured with lymphoma B cells. Because a subset of lymphoma B cells express IL-2 and given that IL-2 signaling is critically important in the development of regulatory T (Treg) cells, we tested the role of IL-2 signaling in TH17 cell development. We found that treatment with anti-IL-2 antibody to interrupt IL-2 signaling significantly inhibited Foxp3 expression in CD4+ T cells. In contrast, interruption of IL-2 signaling up-regulated IL-17 expression in CD4+ T cells and restored lymphoma-mediated down-regulation of IL-17–producing cells. Furthermore, the reversal of Treg cell activity by LPS or CpG-A resulted in an enhancement of IL-17–producing cells. Taken together, our study indicated that lymphoma B cells play an important role in skewing the balance between Treg and TH17 cells resulting in the establishment of a profoundly inhibitory tumor microenvironment. [Cancer Res 2009;69(13):5522–30]
The Journal Club
Shakespeare, William A., Bacon, Douglas R. , Smith, Dale, Rose, Steven H.

Mayo Clinic

Anesthesiology | May 21, 2009 | Volume: 110 | Issue: 6 | Pages: 1214-1216

10.1097/aln.0b013e3181a1628f | PMID 19417606 Get It

Optimizing the Start Time of Statin Therapy for Patients with Diabetes
Denton, Brian T., Kurt, Murat , Shah, Nilay D., Bryant, Sandra C. , Smith, Steven A., Denton, Brian T.

Mayo Clinic

Medical Decision Making | May 8, 2009 | Volume: 29 | Issue: 3 | Pages: 351-367

10.1177/0272989x08329462 | PMID 19429836 Get It

Background . Clinicians often use validated risk models to guide treatment decisions for cardiovascular risk reduction. The most common risk models for predicting cardiovascular risk are the UKPDS, Framingham, and Archimedes models. In this article, the authors propose a model to optimize the selection of patients for statin therapy of hypercholesterolemia, for patients with type 2 diabetes, using each of the risk models. For each model, they evaluate the role of age, gender, and metabolic state on the optimal start time for statins. Method . Using clinical data from the Mayo Clinic electronic medical record, the authors construct a Markov decision process model with health states composed of cardiovascular events and metabolic factors such as total cholesterol and high-density lipoproteins. They use it to evaluate the optimal start time of statin treatment for different combinations of cardiovascular risk models and patient attributes. Results . The authors find that treatment decisions depend on the cardiovascular risk model used and the age, gender, and metabolic state of the patient. Using the UKPDS risk model to estimate the probability of coronary heart disease and stroke events, they find that all white male patients should eventually start statin therapy; however, using Framingham and Archimedes models in place of UKPDS, they find that for male patients at lower risk, it is never optimal to initiate statins. For white female patients, the authors also find some patients for whom it is never optimal to initiate statins. Assuming that age 40 is the earliest possible start time, the authors find that the earliest optimal start times for UKPDS, Framingham, and Archimedes are 50, 46, and 40, respectively, for women. For men, the earliest optimal start times are 40, 40, and 40, respectively. Conclusions . In addition to age, gender, and metabolic state, the choice of cardiovascular risk model influences the apparent optimal time for starting statins in patients with diabetes.